Connecticut Innovations (CI), the leading source of financing and ongoing support for
The funding will help the company conduct engineering and software updates, finalize a beta version of its product, and support additional hospital and clinical case studies. It will also go toward product development and working capital.
"This early-stage company is making considerable advances in cancer immunotherapy," said
Leading pharmaceutical and biotechnology firms have shifted their research to cutting-edge monoclonal antibody therapies that target individual cells to combat cancer and other chronic diseases. IsoPlexis' micro-device and software suite is the first technology that can reliably measure many reactions per cell; the additional information provides a more thorough picture of drug reaction at the cellular level.
"Our breakthrough technology identifies proteins that are important early indicators of efficacy and side effects," said
Connecticut Innovations (CI) is the leading source of financing and ongoing support for
Read the full story at http://www.prweb.com/releases/ConnecticutInnovations/IsoPlexis/prweb12083356.htm
Hispanic #1 Breaking News for Entrepreneurs, Professionals and Small Business Owners - HispanicBusiness.com
OCTOBER 31, 2014
|Customer Service||Policy||Advertise||Site Tools|
|HispanicBusiness Services||Editorial Guidelines||Ad Specifications||Magazine Archive|
|List Rental Agreement||About Us||Media Kits||Post Your Event|
|HireDiversity Job Search||Editorial Calendar||Research|
© 2014 HispanicBusiness Inc. All Rights Reserved.